HRP20150146T1 - Derivati kromenona s protu tumourskom aktivnošä†u - Google Patents

Derivati kromenona s protu tumourskom aktivnošä†u Download PDF

Info

Publication number
HRP20150146T1
HRP20150146T1 HRP20150146TT HRP20150146T HRP20150146T1 HR P20150146 T1 HRP20150146 T1 HR P20150146T1 HR P20150146T T HRP20150146T T HR P20150146TT HR P20150146 T HRP20150146 T HR P20150146T HR P20150146 T1 HRP20150146 T1 HR P20150146T1
Authority
HR
Croatia
Prior art keywords
alkyl
pharmaceutically acceptable
formula
acceptable salt
alkoxy
Prior art date
Application number
HRP20150146TT
Other languages
English (en)
Croatian (hr)
Inventor
Bernard Christophe Barlaam
Sebastien Louis Degorce
Christine Marie Paul Lambert-Van Der Brempt
Remy Robert Morgentin
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20150146T1 publication Critical patent/HRP20150146T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20150146TT 2009-10-27 2010-10-25 Derivati kromenona s protu tumourskom aktivnošä†u HRP20150146T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27
PCT/GB2010/051788 WO2011051704A1 (en) 2009-10-27 2010-10-25 Chromenone derivatives with anti-tumour activity
EP10769052.1A EP2493870B1 (en) 2009-10-27 2010-10-25 Chromenone derivatives with anti -tumour activity

Publications (1)

Publication Number Publication Date
HRP20150146T1 true HRP20150146T1 (hr) 2015-05-22

Family

ID=43085922

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150146TT HRP20150146T1 (hr) 2009-10-27 2010-10-25 Derivati kromenona s protu tumourskom aktivnošä†u

Country Status (41)

Country Link
US (5) US8399460B2 (Direct)
EP (1) EP2493870B1 (Direct)
JP (2) JP5657010B2 (Direct)
KR (1) KR101738195B1 (Direct)
CN (2) CN104447657B (Direct)
AR (1) AR078786A1 (Direct)
AU (1) AU2010311107B9 (Direct)
BR (1) BR112012010124B8 (Direct)
CA (1) CA2776994C (Direct)
CL (1) CL2012001056A1 (Direct)
CO (1) CO6541528A2 (Direct)
CR (1) CR20120217A (Direct)
CU (1) CU20120069A7 (Direct)
CY (1) CY1116143T1 (Direct)
DK (1) DK2493870T3 (Direct)
DO (1) DOP2012000124A (Direct)
EA (1) EA020523B9 (Direct)
EC (1) ECSP12011838A (Direct)
ES (1) ES2530943T3 (Direct)
GT (1) GT201200126A (Direct)
HN (1) HN2012000889A (Direct)
HR (1) HRP20150146T1 (Direct)
IL (1) IL219191A0 (Direct)
IN (1) IN2012DN03328A (Direct)
ME (1) ME02050B (Direct)
MX (1) MX2012005027A (Direct)
MY (1) MY179833A (Direct)
NI (1) NI201200081A (Direct)
NZ (1) NZ599457A (Direct)
PE (1) PE20130149A1 (Direct)
PH (1) PH12012500804A1 (Direct)
PL (1) PL2493870T3 (Direct)
PT (1) PT2493870E (Direct)
RS (1) RS53813B1 (Direct)
SA (1) SA110310808B1 (Direct)
SI (1) SI2493870T1 (Direct)
SM (1) SMT201500036B (Direct)
TW (1) TWI483939B (Direct)
UA (1) UA107474C2 (Direct)
UY (1) UY32978A (Direct)
WO (1) WO2011051704A1 (Direct)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2474147T3 (es) 2008-05-30 2014-07-08 Amgen, Inc Inhibidores de PI3 cinasa
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
UY34013A (es) 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
AU2014208964B2 (en) 2013-01-23 2016-09-01 Astrazeneca Ab Chemical compounds
BR112015019524A8 (pt) * 2013-03-04 2019-11-19 Astrazeneca Ab combinação de um composto [i] com um taxano, método de produção de efeito anticancer, uso de um composto [i] em combinação com um taxano, composição farmacêutica e kit no tratamento de câncer
EA201692267A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
ES2833025T3 (es) 2014-06-13 2021-06-14 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa
SG11201609877XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
WO2015191743A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
CN106573922A (zh) 2014-06-13 2017-04-19 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
ES2905673T3 (es) * 2015-10-09 2022-04-11 Janssen Pharmaceutica Nv Derivados de quinoxalina y piridopirazina como inhibidores de PI3KBETA
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
WO2022164812A1 (en) * 2021-02-01 2022-08-04 Geode Therapeutics Inc. Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
MX2023013080A (es) * 2021-05-03 2023-11-16 Petra Pharma Corp Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
CA3216800A1 (en) * 2021-05-03 2022-11-10 Erin Danielle ANDERSON Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
TWI829179B (zh) * 2021-05-27 2024-01-11 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
CA3232906A1 (en) * 2021-10-07 2023-04-13 Alessandro Boezio Pi3k-alpha inhibitors and methods of use thereof
CN118742545A (zh) * 2021-12-08 2024-10-01 南京征祥医药有限公司 作为PI3Kα抑制剂的稠合杂环化合物
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer
CN119431297A (zh) * 2023-08-02 2025-02-14 郑州同源康医药有限公司 稠环类化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
EP0459983A1 (en) 1988-12-21 1991-12-11 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
DE69127690T2 (de) 1990-06-20 1998-02-12 Pharmacia & Upjohn Company Kal Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP3893026B2 (ja) 1999-02-10 2007-03-14 アストラゼネカ アクチボラグ 血管形成阻害剤としてのキナゾリン誘導体
AU2001230426C1 (en) 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
US7598377B2 (en) * 2002-08-16 2009-10-06 Astrazeneca Ab Inhibition of phosphoinositide 3-kinase β
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
CN101448505A (zh) * 2006-04-04 2009-06-03 加利福尼亚大学董事会 Pi3激酶拮抗剂
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
AR078786A1 (es) 2011-11-30
AU2010311107B9 (en) 2014-06-19
CN102712615B (zh) 2014-12-17
ME02050B (me) 2015-05-20
WO2011051704A1 (en) 2011-05-05
SMT201500036B (it) 2015-05-05
US20160272607A1 (en) 2016-09-22
JP5872016B2 (ja) 2016-03-01
US9718800B2 (en) 2017-08-01
EP2493870B1 (en) 2014-12-17
JP2015078202A (ja) 2015-04-23
ECSP12011838A (es) 2012-06-29
CO6541528A2 (es) 2012-10-16
US20160060240A1 (en) 2016-03-03
CN104447657A (zh) 2015-03-25
US20130158026A1 (en) 2013-06-20
AU2010311107B2 (en) 2014-03-27
BR112012010124A2 (pt) 2016-06-07
DOP2012000124A (es) 2012-07-15
BR112012010124B1 (pt) 2021-02-17
HK1174027A1 (en) 2013-05-31
BR112012010124B8 (pt) 2021-05-25
JP2013508449A (ja) 2013-03-07
US20110098271A1 (en) 2011-04-28
IL219191A0 (en) 2012-06-28
CA2776994A1 (en) 2011-05-05
CN104447657B (zh) 2016-08-17
NI201200081A (es) 2012-11-07
HK1206335A1 (zh) 2016-01-08
KR101738195B1 (ko) 2017-05-19
CA2776994C (en) 2017-10-31
DK2493870T3 (en) 2015-02-23
MX2012005027A (es) 2012-09-07
EA020523B1 (ru) 2014-11-28
RS53813B1 (sr) 2015-06-30
US9029374B2 (en) 2015-05-12
PT2493870E (pt) 2015-02-18
EA020523B9 (ru) 2015-01-30
CY1116143T1 (el) 2017-02-08
US20140194419A1 (en) 2014-07-10
IN2012DN03328A (Direct) 2015-10-23
GT201200126A (es) 2014-03-03
US8673906B2 (en) 2014-03-18
NZ599457A (en) 2014-04-30
SA110310808B1 (ar) 2013-11-24
ES2530943T3 (es) 2015-03-09
PL2493870T3 (pl) 2015-04-30
EP2493870A1 (en) 2012-09-05
TW201121960A (en) 2011-07-01
CN102712615A (zh) 2012-10-03
MY179833A (en) 2020-11-17
SI2493870T1 (sl) 2015-03-31
UY32978A (es) 2011-05-31
KR20120098724A (ko) 2012-09-05
CU20120069A7 (es) 2012-10-15
HN2012000889A (es) 2015-08-03
CR20120217A (es) 2012-06-28
TWI483939B (zh) 2015-05-11
US8399460B2 (en) 2013-03-19
EA201200618A1 (ru) 2012-12-28
UA107474C2 (uk) 2015-01-12
PH12012500804A1 (en) 2022-10-03
PE20130149A1 (es) 2013-03-10
CL2012001056A1 (es) 2012-10-05
AU2010311107A1 (en) 2012-05-03
JP5657010B2 (ja) 2015-01-21

Similar Documents

Publication Publication Date Title
HRP20150146T1 (hr) Derivati kromenona s protu tumourskom aktivnošä†u
CA2987978C (en) Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
JP2016535756A5 (Direct)
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
NZ626942A (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
JP2018531983A (ja) タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
RU2008143550A (ru) Комбинации терапевтических средств, предназначенные для лечения рака
IL260127B (en) mek inhibitors and methods of using them
RU2012120288A (ru) Новые производные нафтиридина и их применение в качестве ингибиторов киназы
HRP20161114T1 (hr) Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama
HRP20121069T1 (hr) Supstituirani derivati amida kao inhibitori protein kinaze
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
RS52274B2 (sr) Jedinjenje diarilhidantoina
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
CA2362715A1 (en) Quinazoline derivatives as angiogenesis inhibitors
JP2016528251A5 (Direct)
MX2009014013A (es) Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
HRP20171053T1 (hr) Derivati oksokinazolinil-butanamida
MX2013011931A (es) Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer.
HRP20210931T1 (hr) Alkil-amin harminski derivati za poticanje rasta kostiju
JP2005511617A5 (Direct)
JP2005506982A5 (Direct)
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
ZA202400988B (en) Aak1 inhibitor and use thereof
CA2428019A1 (en) Estrogen receptor modulators